PLAY PODCASTS
Episode 56: SPONSORED Advances in Stool Testing: The GI-MAP™ GI-Microbial  Assay Plus

Episode 56: SPONSORED Advances in Stool Testing: The GI-MAP™ GI-Microbial Assay Plus

DSL’s GI-MAP stool test is, as CEO Tony Hoffman s…

Dr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigenetics · Dr. Kara Fitzgerald

February 13, 20191h 16m

Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

DSL’s GI-MAP stool test is, as CEO Tony Hoffman states, “a clinician diagnostic tool;” it’s not a microbiome test. Yes, of course the GI-MAP looks at the microbiome, but it's not a broad sweep of the myriad of bugs taking up residence. Rather, it’s a carefully curated investigation of organisms with demonstrated imbalance potential, be it pathogenic or dysbiotic in nature. The test is designed to be user-friendly, interpreted rapidly, logically, providing clearly actionable data that, when addressed, gets results. I’ve known Tony for years; we were both involved in the development of the first stool test using PCR analysis offered to clinicians. He’s brilliant, fun to listen to, and offers loads of pearls in this conversation. Take a listen, share, comment, and let us know what you think!